NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX)
(FSE: J90), a biopharmaceutical company developing
biologically-guided exosome therapy ("ExoTherapy") for patients
with traumatic spinal cord injuries, is pleased to announce a
pioneering collaboration with the German company, Particle Metrix,
a leading provider of particle analysis devices. In connection with
the collaboration, a highly-advanced Nanoparticle Tracking Analysis
instrument ("NTA") has been recently placed. At NurExone’s
laboratory, which is an important milestone in the expansion of
NurExone’s production and analytic processes.
The newly acquired NTA, which is the first of
its kind in Israel, is equipped with state-of-the-art capabilities
including nanoparticle tracking analysis and advanced
colocalization technology. The new system is a ZetaView TWIN Laser
System PMX-230 using wavelengths of 520 and 640 nanometers for
size, concentration, fluorescence, colocalization and Zeta
Potential analysis. As part of the collaboration, the two companies
will share analytical data between them in order to improve the
colocalization performance of the device at these 2
wavelengths.
NurExone plans to leverage the capabilities of
the advanced NTA to validate its methodology for analysis of loaded
exosomes, a vital part of the development process of its ExoPTEN
drug, targeted at the $2.9 billion global market for patients with
acute spinal cord injury. In line with its business strategy
of monetizing its knowledge and capabilities, NurExone will also be
able to offer the NTA services to other companies developing
exosome-based therapies for other indications.
"We firmly believe that exosome-based therapies
have the potential to be the next frontier in drug delivery systems
and are thrilled to collaborate with NurExone and deliver in Israel
for the first time a state-of-the-art ZetaView® TWIN Laser System,"
noted Dr. Clemens Helmbrecht, Managing Director of Particle
Metrix.
"We are delighted to integrate this
one-of-its-kind system into our analytics procedure and quality
control, further advancing our capabilities for analyzing exosomes
loaded with therapeutic cargo," stated Dr. Lior Shaltiel, Chief
Executive Officer of NurExone. "We anticipate a transformative
impact on our quality process in order to develop the highest
quality of life-changing therapies for central nervous system
patients worldwide."
About Particle Metrix
Particle Metrix is an innovative German
technology company at the forefront of nanoparticle analysis
solutions. The state-of-the-art systems provide accurate
measurements of size, concentration, zeta potential, fluorescence
and colocalization of nanoparticles empowering researchers and
engineers to optimize processes, enhance product quality, and drive
scientific advancements. With a commitment to excellence and a
customer-centric approach, Particle Metrix revolutionizes particle
analysis, delivering reliable results and actionable insights to
foster success in diverse scientific and industrial
applications.For further information, please visit
https://particle-metrix.com.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSX Venture
Exchange-listed pharmaceutical company that is developing a
platform for biologically-guided ExoTherapy to be delivered,
non-invasively, to patients who suffered traumatic spinal cord
injuries.
ExoTherapy was conceptually demonstrated in
animal studies at the Technion, Israel Institute of Technology.
NurExone is translating the treatment to humans, and the Company
holds an exclusive worldwide license from the Technion and Tel Aviv
University for the development and commercialization of the
technology.
For additional information, please visit
www.nurexone.com or follow NurExone on LinkedIn, Twitter,
Facebook, or YouTube.
For further information, please contact:
Dr. Lior ShaltielChief Executive Officer and
Director Phone: +972-52-4803034
Inbar Paz-BenayounAdv. Head of Communications and Investor
Relations Phone: +972-52-3966695Email:
info@nurexone.com
Investor Relations (Canada) Phone: +1 905-347-5569Email:
IR@nurexone.com
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking
statements" that reflect the Company's current expectations and
projections about its future development and production process.
When used in this press release, forward-looking statements can be
identified by the use of words such as "may," or by such words as
"will," "intend," "believe," "estimate," "consider," "expect,"
"anticipate," and "objective" and similar expressions or variations
of such words. Forward-looking statements are, by their nature, not
guarantees of the Company's future operational or financial
performance and are subject to risks and uncertainties and other
factors that could cause the Company's actual results, performance,
prospects, or opportunities to differ materially from those
expressed in, or implied by, these forward-looking statements. No
representation or warranty is intended with respect to anticipated
future results, or that estimates, or projections will be
sustained.
Forward-looking statements are necessarily based
on estimates and assumptions made by us in light of our experience
and perception of historical trends, current conditions, and
expected future developments, as well as the factors we believe are
appropriate. Forward- looking statements in this press release
include, but are not limited to, statements relating to: the uses
and implementation of the NTA; our future plans and intellectual
property; our scientific and development activities; future
scientific activities and the treatment of certain conditions; the
therapeutic benefits, effectiveness, and safety of our product
candidates; and the estimated growth of the market for acute spinal
cord injuries.
In developing the forward-looking statements in
this press release, we have applied several material assumptions,
our ability to retain key personnel, our ability to continue
investing in research and development, our ability to secure
available funding and to continue as a going concern; the general
business and economic conditions of the industries and countries in
which we operate; and our ability to execute on our business
strategy.
Many risks, uncertainties, and other factors
could cause the actual results of the Company to differ materially
from the results, performance, achievements, or developments
expressed or implied by such forward-looking statements. These
risks, uncertainties, and other factors include, but are not
limited to, the following: those risk factors identified under the
heading "Risk Factors" on pages 29 to 36 of the Company's Annual
Information Form dated March 30, 2023, a copy of which is available
under the Company's SEDAR profile at www.sedar.com; risks related
to the Company's early stage of development; lack of revenues to
date; government regulation; market acceptance for our products;
rapid technological change; dependence on key personnel; protection
of our intellectual property; dependence on our strategic partners;
overall economic conditions; competitive pressures; network
restrictions; and other similar factors that may cause the actual
results, performance or achievements to differ materially from
those expressed or implied in these forward-looking statements.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of the
press release or as of the date otherwise specifically indicated
herein. Due to risks and uncertainties, events may differ
materially from current expectations. The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, except as required pursuant to applicable securities
law. All forward-looking statements contained in the press release
are expressly qualified in their entirety by this cautionary
statement.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Nurexone Biologic (TSXV:NRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Nurexone Biologic (TSXV:NRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024